Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:GNMX

Aevi Genomic Medicine (GNMX) Stock Price, News & Analysis

Aevi Genomic Medicine logo

About Aevi Genomic Medicine Stock (NASDAQ:GNMX)

Advanced Chart

Key Stats

Today's Range
$0.15
$0.18
50-Day Range
$0.17
$0.19
52-Week Range
$0.11
$0.35
Volume
2.95 million shs
Average Volume
3.16 million shs
Market Capitalization
$12.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Receive GNMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aevi Genomic Medicine and its competitors with MarketBeat's FREE daily newsletter.

GNMX Stock News Headlines

Plc Astrazeneca's Net Worth
Aevi Genomic Medicine, Inc.
Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
See More Headlines

GNMX Stock Analysis - Frequently Asked Questions

Aevi Genomic Medicine, LLC (NASDAQ:GNMX) released its quarterly earnings data on Thursday, November, 1st. The biotechnology company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.03.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aevi Genomic Medicine investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), SCYNEXIS (SCYX), Protalix BioTherapeutics (PLX), iBio (IBIO), Immunomedics (IMMU) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

Last Earnings
11/01/2018
Today
5/06/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:GNMX
Previous Symbol
NASDAQ:MDGN
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-30,770,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.12 per share
Price / Book
1.38

Miscellaneous

Free Float
N/A
Market Cap
$12.89 million
Optionable
Optionable
Beta
1.13
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:GNMX) was last updated on 5/6/2025 by MarketBeat.com Staff
From Our Partners